Roman Butler Fullerton & Co. Acquires New Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Roman Butler Fullerton & Co. acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 31,505 shares of the biotechnology company’s stock, valued at approximately $378,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Mesirow Institutional Investment Management Inc. purchased a new stake in shares of ADMA Biologics in the first quarter valued at approximately $17,221,000. Rice Hall James & Associates LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter worth $7,963,000. Castleark Management LLC bought a new position in shares of ADMA Biologics during the 1st quarter worth $5,400,000. Hillsdale Investment Management Inc. grew its position in shares of ADMA Biologics by 41,893.3% during the 1st quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company’s stock worth $4,157,000 after buying an additional 628,400 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of ADMA Biologics by 90.7% during the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock valued at $7,717,000 after buying an additional 556,175 shares during the period. 75.68% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Adam S. Grossman sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the sale, the chief executive officer now directly owns 2,081,475 shares in the company, valued at approximately $22,313,412. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Raymond James upped their price objective on shares of ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 10th. HC Wainwright increased their price objective on shares of ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research note on Monday. Cantor Fitzgerald lifted their price objective on shares of ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a report on Friday. Finally, Mizuho upped their target price on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $15.50.

ADMA Biologics Stock Performance

ADMA stock traded up $0.82 during midday trading on Tuesday, reaching $17.27. The stock had a trading volume of 4,942,288 shares, compared to its average volume of 3,042,754. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.86 and a current ratio of 5.21. The firm has a fifty day simple moving average of $11.90 and a two-hundred day simple moving average of $8.47. The stock has a market cap of $4.00 billion, a PE ratio of -848.00 and a beta of 0.55. ADMA Biologics, Inc. has a 52-week low of $3.06 and a 52-week high of $17.30.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The firm had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. During the same period last year, the company earned ($0.02) earnings per share. ADMA Biologics’s revenue for the quarter was up 78.4% compared to the same quarter last year. As a group, equities research analysts anticipate that ADMA Biologics, Inc. will post 0.35 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.